STOCK TITAN

BrainsWay to Present at the Sidoti December Micro-Cap Investor Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

BURLINGTON, Mass. and JERUSALEM, Nov. 30, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that Christopher von Jako, Ph.D., President and Chief Executive Officer, will present and participate in one-on-one investor meetings at the Sidoti December Micro-Cap Investor Conference.

Event: Sidoti December Virtual Micro-Cap Investor Conference
Date: December 8-9, 2021
Presentation: December 9, 2021, at 10 am EST
Webcast: https://sidoti.zoom.us/webinar/register/WN_VPWAO69rSE6J1Tp9kGmQVw

Management will also meet with investors during the event. Investors interested in meeting with the BrainsWay management team during the conference should contact their Sidoti representative.

About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.

Contacts:
Scott Areglado
SVP and Chief Financial Officer
617-771-2287
SAreglado@brainsway.com 

Investors:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com        


BrainsWay Ltd.

NASDAQ:BWAY

BWAY Rankings

BWAY Latest News

BWAY Stock Data

89.09M
24.69M
5.01%
24.07%
0.45%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
Jerusalem

About BWAY

brainsway is a leading global neurmodulation company with headquarters in jerusalem and the us. our patented breakthrough technology has already treated over 10,000 patients, and has helped usher in a new era in brain disorder treatment. a non-invasive, yet highly effective solution for brain disorders, brainsway has helped thousands of patients across the world, from the unites states to europe to south america, and has the potential to make a difference in the well-being and health of millions of patients worldwide. brainsway's technology offers a much needed alternative for millions of patients from a bleak cycle of insufficiently effective treatments and unpleasant side effects. brainsway's treatment has fda approval for treating patients with major depressive disorder*. the technology is safe, with no systemic or long-term side effects, in addition to being highly convenient, requiring only brief daily sessions over a few weeks. in addition to being used to treat depression daily